Many biopharmaceuticals are only available as powders for reconstitution. This often limits the convenience of use and could increase the risk of dosing errors. This is particularly the case for self-administered drugs.

Arecor has successfully applied the Arestat-T™ technology to a number of important self-administered proteins presently only available as powders for reconstitution. The clotting factors, in particular Factors VIII and IX are good examples. Both clotting factors are used in the treatment of haemophilia, a genetic disorder which leaves sufferers with an inability to form blood clots. Consequently, haemophilia sufferers are infused with a therapeutic dose of reconstituted Factor VIII or IX through an intravenous delivery device. To make this more convenient to patients for self-administration, there is a need for stable aqueous formulations. In conjunction with the National Institute for Biological Standards and Control (NIBSC), Arecor has developed aqueous formulations of Factor VIII and Factor IX demonstrating that dry powder formulations for reconstitution can be replaced by stable liquids, with a positive impact on the treatment regime.